Pomegranate is one of the few foods where randomised controlled trial evidence in humans is available for multiple health outcomes. Its primary active compounds are ellagitannins including punicalagins, which are converted by gut bacteria to urolithins. Urolithin A in particular has been the subject of intensive research: it activates mitophagy, the cellular process for removing damaged mitochondria, and has anti-inflammatory, anti-proliferative, and muscle-protective effects.
The Clinical Evidence
- Cardiovascular: a 2004 RCT in patients with carotid artery stenosis found that 240ml pomegranate juice daily for 1 year reduced carotid intima-media thickness (a measure of atherosclerosis progression) by 30 percent while the control group showed 9 percent worsening; LDL oxidation was reduced by 90 percent
- Blood pressure: a meta-analysis of 8 RCTs found pomegranate juice significantly reduced both systolic and diastolic blood pressure, with effects comparable to ACE inhibitor medication in some trials
- Prostate: preliminary RCT evidence (though industry-funded) found pomegranate juice extended PSA doubling time in prostate cancer patients; independent confirmation is needed
- Muscle recovery: a recent RCT found that pomegranate extract reduced muscle damage markers and accelerated recovery from eccentric exercise, consistent with its anti-inflammatory and antioxidant mechanisms
pomegranate health researchpomegranate cardiovascular studyurolithins pomegranate researchpomegranate cancer preventionellagitannins health benefits